Literature DB >> 6586058

Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites.

A Björklund, U Stenevi, R H Schmidt, S B Dunnett, F H Gage.   

Abstract

Dissociated dopamine-rich cell suspensions were prepared from the ventral mesencephalon of rat embryos and injected in one or several sites in striatal and non-striatal regions in the dopaminergically denervated brain of adult rats. While the grafts survived well in all sites, the dopamine fibre outgrowth was markedly different depending on whether the grafts occurred in an area normally innervated by the mesencephalic dopamine neurones (i.e. neostriatum or nc. accumbens) or in areas not normally innervated by these neurones (i.e. parietal cortex, lateral hypothalamus or substantia nigra). Moreover, in grafts placed at different sites along the trajectory of the nigrostriatal pathway the outgrowing fibres remained confined to the graft, and there was little evidence that the implanted neurones could elongate their axons along the pathway of the nigrostriatal tract to reach the striatum from a distance. Thus, the intracerebral suspension grafts provided efficient reinnervation of a denervated target only when placed in the immediate vicinity of the target area. The results of multiple graft placements indicate that a relatively complete restoration of a lost innervation should be possible to achieve in large areas of the brain, such as the striatal complex, with the suspension grafting technique.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6586058

Source DB:  PubMed          Journal:  Acta Physiol Scand Suppl        ISSN: 0302-2994


  40 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

Review 2.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Intraparenchymal grafting of cerebellar cell suspensions to the deep cerebellar nuclei of pcd mutant mice, with particular emphasis on re-establishment of a Purkinje cell cortico-nuclear projection.

Authors:  L C Triarhou; W C Low; B Ghetti
Journal:  Anat Embryol (Berl)       Date:  1992

Review 4.  Transplantation of embryonic dopamine neurons: what we know from rats.

Authors:  S B Dunnett
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

5.  Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.

Authors:  S B Blunt; P Jenner; C D Marsden
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

6.  Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues.

Authors:  S B Dunnett; T D Hernandez; A Summerfield; G H Jones; G Arbuthnott
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

7.  Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease.

Authors:  T K Huffaker; B D Boss; A S Morgan; N T Neff; R E Strecker; M S Spence; R Miao
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

8.  Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior.

Authors:  I Strömberg; M Herrera-Marschitz; U Ungerstedt; T Ebendal; L Olson
Journal:  Exp Brain Res       Date:  1985       Impact factor: 1.972

9.  Comparison of adrenal and foetal nigral grafts on drug-induced rotation in rats with 6-OHDA lesions.

Authors:  V J Brown; S B Dunnett
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.